s 16020-2 has been researched along with olivacine in 4 studies
| Studies (s 16020-2) | Trials (s 16020-2) | Recent Studies (post-2010) (s 16020-2) | Studies (olivacine) | Trials (olivacine) | Recent Studies (post-2010) (olivacine) |
|---|---|---|---|---|---|
| 20 | 2 | 1 | 29 | 1 | 10 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atassi, G; Bisagni, E; Burbridge, M; Guilbaud, N; Jan, M; Kraus-Berthier, L; Pierré, A; Rouillon, MH; Saint-Dizier, D; Visalli, M | 1 |
| Atassi, G; Jacquemin-Sablon, A; Le Mée, S; Markovits, J; Pierré, A; Saucier, JM | 1 |
| Berlion, M; Bourhis, J; Eschwege, F; Frascogna, V; Lucas, C; Maggiorella, L; Poullain, MG; Razy, SD | 1 |
| Awada, A; Bleiberg, H; Brillanceau, MH; Calvo, F; De Valeriola, D; Dosquet, C; Eftekhary, P; Gerard, B; Giacchetti, S; Giroux, B; Lucas, C; Marty, M; Piccart, M; Poullain, MG; Soudon, J | 1 |
1 trial(s) available for s 16020-2 and olivacine
| Article | Year |
|---|---|
Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules.
Topics: Adult; Aged; Biological Availability; Carbazoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Ellipticines; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyridines; Risk Assessment; Sensitivity and Specificity; Treatment Outcome | 2002 |
3 other study(ies) available for s 16020-2 and olivacine
| Article | Year |
|---|---|
In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Blood Cell Count; Bone Marrow; Breast Neoplasms; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Ellipticines; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Leukemia P388; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Tumor Cells, Cultured | 1996 |
S16020-2, a new highly cytotoxic antitumor olivacine derivative: DNA interaction and DNA topoisomerase II inhibition.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line; Cell Survival; Circular Dichroism; Cricetinae; DNA; DNA Damage; DNA Ligases; Ellipticines; Spectrophotometry, Ultraviolet; Topoisomerase II Inhibitors | 1998 |
The olivacine S16020 enhances the antitumor effect of ionizing radiation without increasing radio-induced mucositis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carbazoles; Cell Division; Combined Modality Therapy; Ellipticines; Female; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Mouth Mucosa; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Pyridines; Radiotherapy; Stomatitis; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |